A novel drug developed in St. Louis for the treatment of rheumatoid arthritis is being investigated as a possible treatment for COVID-19. The anti-inflammatory drug, ATI-450, is informally named after drug maker Aclaris Therapeutics, Inc. with an assigned number. The drug was developed in St. Louis by Aclaris’ research and development company, Confluence Discovery Technologies, located at the BioGenerator in the Cortex Innovation Community. The first human clinical trial involving rheumatoid arthritis patients was in 2019. The trial successfully tested the safety and efficacy of ATI-450 in patients. The FDA has allowed the company to evaluate ATI-450 in a small clinical trial for hospitalized patients with COVID-19.
Subscribe now ➤
For more great content from the Higher Education Channel check us out at:
Facebook ➤
Twitter ➤
Instagram ➤
